United Therapeutics Corp [UTHR] stock is trading at $357.55, down -5.83%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The UTHR shares have lost -1.27% over the last week, with a monthly amount drifted -0.46%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
United Therapeutics Corp [NASDAQ: UTHR] stock has seen the most recent analyst activity on July 11, 2024, when Morgan Stanley downgraded its rating to a Equal-Weight and also boosted its price target to $321 from $310. Previously, Goldman upgraded its rating to Neutral on February 12, 2024, and elevated its price target to $215. On February 05, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $330 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $309 on December 08, 2023. UBS initiated its recommendation with a Buy and recommended $320 as its price target on December 06, 2022. Goldman started tracking with a Sell rating for this stock on December 05, 2022, and assigned it a price target of $230. In a note dated October 11, 2022, Morgan Stanley initiated an Overweight rating and provided a target price of $288 on this stock.
United Therapeutics Corp [UTHR] stock has fluctuated between $208.62 and $417.82 over the past year. Currently, Wall Street analysts expect the stock to reach $440.4 within the next 12 months. United Therapeutics Corp [NASDAQ: UTHR] shares were valued at $357.55 at the most recent close of the market. An investor can expect a potential return of 23.17% based on the average UTHR price forecast.
Analyzing the UTHR fundamentals
United Therapeutics Corp [NASDAQ:UTHR] reported sales of 2.76B for the trailing twelve months, which represents a growth of 22.89%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at 0.46%, Pretax Profit Margin comes in at 0.52%, and Net Profit Margin reading is 0.4%. To continue investigating profitability, this company’s Return on Assets is posted at 0.16, Equity is 0.19 and Total Capital is 0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 348.07 points at the first support level, and at 338.60 for the second support level. However, for the 1st resistance point, the stock is sitting at 375.01, and for the 2nd resistance point, it is at 392.48.
Ratios To Look Out For
For context, United Therapeutics Corp’s Current Ratio is 4.58. As well, the Quick Ratio is 4.41, while the Cash Ratio is 1.78. Considering the valuation of this stock, the price to sales ratio is 5.79, the price to book ratio is 2.61 and price to earnings (TTM) ratio is 15.70.
Transactions by insiders
Recent insider trading involved LOUIS W. SULLIVAN, Director, that happened on Dec 18 ’24 when 26209.0 shares were purchased. PRESIDENT AND COO, BENKOWITZ MICHAEL completed a deal on Dec 16 ’24 to sell 10000.0 shares. Meanwhile, Officer Michael Benkowitz bought 40000.0 shares on Dec 16 ’24.
